Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults.

Trial Profile

Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Telithromycin (Primary)
  • Indications Bacterial infections; Chronic bronchitis
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Planned number of patients changed from 100 to 54 as reported by ClinicalTrials.gov.
    • 03 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top